Natural killer t cell ligand loaded extracellular nanovesicle and autologous anti-cancer vaccine for hematologic malignancies comprising the same

Abstract

The present invention provides a natural killer T cell ligand-loaded extracellular nanovesicle, and an autologous anticancer vaccine for hematologic malignancies including the above extracellular nanovesicle. More particularly, a cancer cell-derived extracellular nanovesicle in which a natural killer T cell ligand as an adjuvant is bound to a surface thereof, and an autologous anticancer vaccine including the same, which can recognize cancer antigens specific to patients with hematologic malignancies and has cancer cell-specific anticancer function thus to enable T cell activation.

Dependencies are inferred from the claim text.